Vol 3 Issue 1
Short-term Studentship Project: KAP study on the Function of WHO Pauly1, Pawarsarvesh2, Prachi Gupta3, Prachi Jindal4, Pragya Singh51,2,3,4,5Batch 2022 MBBS Students, Department of Community Medicine, Rama Medical College Hospital & Research Center Corresponding author: Pauly – [email protected] Pragya singh – [email protected] Sarvesh Pawar- [email protected] Prachi Gupta, 4. Prachi Jindal – [email protected]
Safety and Efficacy of different Classes of Insulin as Add on Therapy of oral hypoglycemic agents in uncontrolled Type 2 Diabetes Ashritha Kudikala1, Haripriya Kanaparthi, Mahibul Islam1, Satish Chinnala2 Abstract Aim: This study aims to evaluate the safety and efficacy of insulin as an adjunct therapy to one or More oral hypoglycaemic agents in patients withuncontrolled type 2 diabetes (T2D).Objectives: Assess the impact of insulin therapy on achieving the target blood glucose and glycated hemoglobin (HbA1c) levels. Examine the long-term effects of combining insulin therapy with oral hypoglycaemic agents on cardiovascular outcomes and overall mortality. Evaluate patient adherence to insulin therapy, considering factors influencing compliance such as dosing regimen, injection technique, and lifestyle adjustments.Results: The study involved 350 patients (183 females and 167 males) receiving various diabetes treatments: 230 on oral hypoglycaemics, 23 oninsulin, and 68 on a combination of therapies. A significant HbA1c reduction from 7.71% to 5.33% was observed. Mean FBS, post-FBS, and PPBS were166.57, 172.86, and 248.57 mg/dL, indicating improved glycaemic control. Conclusion: This study highlights the need for improved strategies to enhance compliance and adherence to treatment, address social habits, andmanage weight effectively. By optimizing insulin therapy alongside oral hypoglycaemics, healthcare providers can significantly improve glycaemiccontrol and overall health outcomes in patients with uncontrolled T2D. Keywords: Type 2 diabetes, insulin, oral hypoglycaemic drugs, adherence.
The effect of dried camel milk on Type 1 Diabetes on Insulin Therapy T. Mohammadabadi1, R. Jain2, R. Shoghli3, S. Agarwal4, S. Tiwari4, S. Verma4, P. Taneja4, A. Pratap5.1Agricultural Sciences and Natural Resources University, Faculty of Animal Science and Food Technology, Iran.2Jain hospital & Research Centre Pvt Ltd, Medicine, Kanpur, India.3University of Helsinki, Medicine, Helsinki, Finland.4GSVM Medical College, Obstetrics and Gynaecology, Kanpur, India.5SRTR Medical college, community medicine, Ambajogai, India Abstract Background Traditionally, in Africa, Asia, and the Middle East, camel milk is consumed regularly to manage diabetes, and drinking it lowers the incidence of diabetes. Since fresh camel milk is not available to all people globally, this study aimed to evaluate the antidiabetic effects of camel milk powder in diabetic patients. Camel milk has immune-stimulatory properties on the beta-cells of the pancreas, enhanced secretion of insulin, and decreased insulin resistance in diabetic subjects[1] Aim Evaluation of Camel milk in Type 1 Diabetes: Blood parameters prospective study Methods: In this trial, 6 type 1 diabetic cases who had been on insulin for the last few years were selected and given 15-gram camel milk powder/day, equivalent to about 500 mL of camel milk, twice daily in divided doses for 3 months. Patients were not on any other medications except insulin or dietary regimens or exercises at least one month before the trial. Results The results showed a significant decrease in fasting and postprandial blood Glucose in patients fed camel milk powder, from 113 to 98 mg/dL (P = 0.001) and from 142 to 131 mg/dL (P = 0.02), respectively, after 3 months of taking camel milk powder. The LDL decreased significantly from 95 to 73 mg/dL(P0.02). Thus, camel milk powder may exhibit antidiabetic activity in patients with diabetes and improve cardiovascular health and other complications. The results also showed that the average required insulin dose before consuming camel milk powder was 42 ± 5 u/day, gradually decreasing to 30 ± 6 u/day (P = 0.02) three months after taking camel milk powder.
Primary Neonatal Outcomes in the metformin and MNT group in Early Trimester with Early Gestational Glucose Intolerance S. Agarwal1, S. Tiwari1, S. Verma1, P. Taneja1, S. Veeraswamy2, R. Jain3, P. Saxena4, A. Chandrasekar5, B.Natarajan6.1GSVM Medical College, Obstetrics and Gynaecology, Kanpur, India. 2The MGR Tamilnadu Medical University, Obstetrics and Gynecology, Chennai, India. 3 Jain Hospital & Research Centre Pvt Ltd, Medicine, Kanpur, India. 4 LHMC Medical College, Obstetrics and Gynaecology, New Delhi, India. 5 Madha Medical College and Research Institute, Obstetrics & Gynaecology, Chennai, India.6 SRC Diabetes Centre-, Diabetes, Erode, India Abstract MethodA study included pregnant women at 8 to 10 weeks of gestation, divided into two groups based on their blood sugar levels of≥110 mg/dl. Those with high levels ≥110 mg/dl received two different interventions: Metformin-MNT and MNT only. Follow-up outcomes were done until delivery.ResultsPrimary Outcomes* The Adverse neonatal composite outcomes in the groups were 35 (37.6%) vs 55 (52.3), which were statistically significant (P = 0.038), but the Primary Maternal hypertension composite outcomes were not significant (9 (9.6%) vs 10 (10.7%), P = 0.80) (Table 1). IUD/Spontaneous abortion 8-28 Weeks and stillbirth are 20 (16) and 12(9.6) in the MNT Group compared to nil in the MNT-Metformin intervention group, which is highly significant.Conclusion: It’s important to keep maternal 2-hour postprandial blood glucose (PPBG) levels below 110 mg/dL in the 10th week of pregnancy to prevent fetal hyperinsulinemia and improve maternal-fetal health.
Early Management of Early Gestational Glucose Intolerance V. Seshiah1, P. Saxena2, A. Chandersekhar3, N. Bhavatharini4, G. Lakshmi5, B. .Madhuri6, S. Agarwal7,, S. Tiwari7, S. Verma7, R. Jain8 . 1The Tamilnadu Dr. MGR. Medical University, Chennai, India; Medicine, Chennai, India.2 LHMC, Obstetrics and Gynecology, New Delhi, India.3 Madha Medical College and Research Institute, Obstetrics and Gynecology, Chennai, India.4 SRC Diabetes Centre, Diabetes, Erode, India.5Chennai, Obstetrics and Gynaecology, Chennai, India.. 6Diabetes in pregnancy study Group of India, Diabetes, Chennai, India.7GSVM Medical College, Obstetrics and Gynaecology, Kanpur, India.. 8Jain Hospital & Research Center Pvt Ltd, Medicine, Kanpur, India. 1The Tamilnadu Dr. MGR. Medical University, Chennai, India; Medicine, Chennai, India.2 LHMC, Obstetrics and Gynaecology, New Delhi, India.3 Madha Medical College and Research Institute, Obstetrics and Gynecology, Chennai, India.4 SRC Diabetes Centre, Diabetes, Erode, India.5Chennai, Obstetrics and Gynaecology, Chennai, India.. 6Diabetes in pregnancy study Group of India, Diabetes, Chennai, India.7GSVM Medical College, Obstetrics and Gynaecology, Kanpur, India.. 8Jain Hospital & Research Center Pvt Ltd, Medicine, Kanpur, India.
